Omnicell (NASDAQ:OMCL) Trading Down 7%

Omnicell, Inc. (NASDAQ:OMCL - Get Free Report) dropped 7% during mid-day trading on Wednesday . The company traded as low as $26.56 and last traded at $26.63. Approximately 38,788 shares were traded during trading, a decline of 93% from the average daily volume of 556,987 shares. The stock had previously closed at $28.64.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on the stock. Barclays began coverage on shares of Omnicell in a report on Wednesday, January 3rd. They issued an "underweight" rating and a $33.00 target price on the stock. Benchmark cut their target price on shares of Omnicell from $42.00 to $38.00 and set a "buy" rating for the company in a research note on Friday, February 9th. Finally, Wells Fargo & Company cut their price objective on Omnicell from $28.00 to $26.00 and set an "equal weight" rating for the company in a research report on Friday, February 9th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and three have issued a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of "Hold" and an average price target of $42.20.

Omnicell Stock Down 4.2 %

The firm's 50-day moving average is $28.25 and its two-hundred day moving average is $33.71. The company has a debt-to-equity ratio of 0.48, a quick ratio of 2.22 and a current ratio of 2.52. The stock has a market cap of $1.26 billion, a P/E ratio of -60.98 and a beta of 0.76.

Omnicell (NASDAQ:OMCL - Get Free Report) last released its earnings results on Thursday, February 8th. The company reported $0.12 earnings per share for the quarter, topping analysts' consensus estimates of ($0.10) by $0.22. Omnicell had a positive return on equity of 3.43% and a negative net margin of 1.78%. The company had revenue of $258.85 million during the quarter, compared to the consensus estimate of $256.00 million. On average, equities research analysts anticipate that Omnicell, Inc. will post 0.1 earnings per share for the current year.

Institutional Investors Weigh In On Omnicell

A number of institutional investors and hedge funds have recently modified their holdings of OMCL. Versant Capital Management Inc increased its stake in Omnicell by 561.4% in the 3rd quarter. Versant Capital Management Inc now owns 549 shares of the company's stock valued at $25,000 after buying an additional 466 shares during the last quarter. Belpointe Asset Management LLC increased its position in shares of Omnicell by 92.2% in the first quarter. Belpointe Asset Management LLC now owns 494 shares of the company's stock valued at $29,000 after acquiring an additional 237 shares during the last quarter. KBC Group NV bought a new stake in Omnicell during the fourth quarter worth about $38,000. Covestor Ltd boosted its position in Omnicell by 65.6% during the third quarter. Covestor Ltd now owns 1,355 shares of the company's stock valued at $61,000 after purchasing an additional 537 shares during the last quarter. Finally, Acadian Asset Management LLC bought a new position in Omnicell in the third quarter valued at approximately $62,000. 97.70% of the stock is owned by institutional investors.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.